Posts Tagged ‘Antihistamine’

Drug Helps Brain Grow New Cells

Tuesday, August 24th, 2010

Researchers have found a drug that can help the brain grow new cells, and they said their study may lead to ways to improve experimental Alzheimer’s drugs.

The researchers’ work, done on rodents, builds on findings that all mammals, including humans, make brain cells throughout their lives. Most of these die, but this drug helps more of the baby cells survive and grow to become functioning brain cells.

“We make new neurons every day in our brain,” Andrew Pieper of the University of Texas Southwestern Medical Center in Dallas who worked on the study, said in a telephone interview. “What our compound does is allow more of them to survive.”

The compound is called P7C3 for now, and the researchers have already started tweaking it to make it more effective. They said it seems safe and appears to work even when taken as a pill.

The compound is similar to Medivation and Pfizer experimental Alzheimer’s drug, Dimebon, and may provide ways to improve its effects, Pieper and colleagues reported in the journal Cell.

It is also similar to some compounds owned by Serono, the researchers said.

Dimebon, originally a Russian-made antihistamine also known as latrepirdine, failed in a clinical trial for Alzheimer’s disease in March.

“For the sake of patients suffering from Alzheimer’s disease, it is hoped that the apparently marginal clinical utility of Dimebon might be enhanced by improvements in both its potency and ceiling of proneurogenic, neuroprotective efficacy,” the researchers wrote.

“If so, our work offers concrete assays for the development of improved versions of these neuroprotective drugs.”

Alzheimer’s gradually destroys the brain and affects 26 million people globally. Drugs, such as Pfizer’s Aricept, improve symptoms only minimally.

The researchers went through 1,000 representative compounds from 300,000 chemicals, pooled them, and administered them to mice. They then dissected the brains to see whether any of the mice had made new cells in the hippocampus, a region of the brain associated with learning and memory.

They eventually narrowed the field to P7C3.

When they gave it to old rats for two months, the elderly rodents did far better than other old rats in learning their way around a water maze.

When dissected, the treated rats turned out to have three times the usual number of newborn neurons in a brain region called the dentate gyrus.

They made a derivative of P7C3 called A20 that worked even better

When the researchers tested Dimebon and the Serono compounds, they found these drugs also stimulated the growth of new brain cells. Being able to target their effects could lead to better drugs to treat Alzheimer’s and perhaps other diseases that destroy brain cells like strokes and amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease.

“This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease,” said Dr. Thomas Insel, director of the National Institute on Mental Health, which helped pay for the study.

http://www.wpgauto.com/

Wpg Auto site

Quality Inn Winnipeg Extended Stay Hotel

Canadian  Fleet

Derrick Dodge

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Sugar, The Other White Drug I appreciate all your comments on my previous post about sugar addiction. This topic has really got me thinking! I’d like to explore it further. If truth be told, I...
  • Solution to Sugar Addiction I've talked about the possibility of being addicted to sugar and more of the specifics on how sugar acts like a drug in some individuals. This post will cover the...
  • Judge stops federal funding of embryonic stem cell research [/caption] Washington -- A U.S. district judge granted a preliminary injunction Monday to stop federal funding of embryonic stem cell research that he said destroys embryos, ruling it went against...
  • Persijap Never Hold Players JEPARA - Management Persijap cold response of a number of pillars which began looking for a new port for the competition next season. One of them is a goal machine...
  • HP buying Palm for 1.2 billion dollars [/caption] US computer giant Hewlett-Packard, in a bid to become a player in the fast-growing smartphone market, said Wednesday it was buying struggling US mobile phone maker Palm for 1.2...
  • The Business of Blogging One of the main problems facing corporate bloggers is that they do not treat their blogs like a business, and they may not take them seriously enough. There are fortunes...
  • Children exposed daily to untested personal-care products (Source: Environmental Working Group) – From baby shampoo to diaper wipes, children are exposed every day to products containing chemicals that have not been assessed for their hazards to children,...

A pill to make you smarter? Drug grows brain cells

Tuesday, August 10th, 2010

Researchers have found a drug that can help the brain grow new cells and said their study may lead to ways to improve experimental Alzheimer’s drugs.

The researchers’ work, done on rodents, builds on findings that all mammals, including humans, make brain cells throughout their lives. Most of these die, but this drug helps more of the baby cells survive and grow to become functioning brain cells.

“We make new neurons every day in our brain,” Andrew Pieper of the University of Texas Southwestern Medical Centre in Dallas who worked on the study, said in a telephone interview. “What our compound does in allow more of them to survive.”

The compound is called P7C3 for now, and the researchers have already started tweaking it to make it more effective. They said it seems safe and appears to work even when taken as a pill.

The compound is similar to Medivation Inc (MDVN.O) and Pfizer Inc’s (PFE.N) experimental Alzheimer’s drug, Dimebon, and may provide ways to improve its effects, Pieper and colleagues reported in the journal Cell.

It is also similar to some compounds owned by Serono, the researchers said.

Dimebon, originally a Russian-made antihistamine also known as latrepirdine, failed in a clinical trial for Alzheimer’s disease in March.

“For the sake of patients suffering from Alzheimer’s disease, it is hoped that the apparently marginal clinical utility of Dimebon might be enhanced by improvements in both its potency and ceiling of proneurogenic, neuroprotective efficacy,” the researchers wrote.

“If so, our work offers concrete assays for the development of improved versions of these neuroprotective drugs.”

Alzheimer’s gradually destroys the brain and affects 26 million people globally. Drugs, such as Pfizer’s Aricept, improve symptoms only minimally.

OLD RATS, NEW TRICKS

The researchers went through 1,000 representative compounds from 300,000 chemicals, pooled them and administered them to mice. They then dissected the brains to see whether any of the mice had made new cells in the hippocampus, a region of the brain associated with learning and memory.

They eventually narrowed the field to P7C3.

When they gave it to old rats for two months, the elderly rodents did far better than other old rats in learning their way around a water maze.

When dissected, the treated rats turned out to have three times the usual number of newborn neurons in a brain region called the dentate gyrus.

They made a derivative of P7C3 called A20 that worked even better.

When the researchers tested Dimebon and the Serono compounds, they found these drugs also stimulated the growth of new brain cells. Being able to target their effects could lead to better drugs to treat Alzheimer’s and perhaps other diseases that destroy brain cells like strokes and amyotrophic lateral sclerosis, also know as ALS or Lou Gehrig’s disease.

“This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease,” said Dr. Thomas Insel, director of the National Institute on Mental Health, which helped pay for the study.

http://www.dimebonalzheimers.com/

Dimebon Over Counter Treatment

One Hour Canada

Furnasman New Homes

Furnasman Winnipeg

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Pfizer’s Lemons

Thursday, May 27th, 2010

When it comes to shopping around for new drugs from biotech partners, Pfizer is a bit like a naive used car buyer. It seems to pay a lot of attention to the gloss on the surface, and not enough to whether the engine inside will work.

How else can you explain the company shelling out $225 million on  the Alzheimer’s drug Dimebon from Medivation?  In its first big trial last week, the drug showed no effect whatsoever on Alzheimer’s symptoms. The result is so bad it raises serious questions about what Pfizer was thinking when it licensed the drug two years ago.

From a chemistry perspective, the old antihistamine was never anything special, University of Southern California Alzheimer’s expert Lon Schneider has pointed out. But Pfizer (apparently) got excited based on one smallish trial with promising results conducted entirely in Russia. There also was a lot of buzz about the drug doing something special to mitochrondria. In fact, the mechanism of the drug was always murky.

Over the years, Pfizer has bought enough biochemical duds to fill an entire junkyard.  Here is a list of some of Pfizer’s past lemons:

Exubera
Pfizer spent billions and many years and testing this version of inhaled insulin, even as after the gadget got ever more clunky and the drug was linked to signs of decreased lung function. It finally pulled the plug in 2007.

Macugen
Pfizer licensed this drug for macular degeneration for $300 million, but it has been a commercial flop.

Esperion Therapeutics
In 2003, Pfizer paid $1.3 billion for this company testing a protein “Roto-Rooter” for clogged arteries. After the deal, hardly a peep was heard about the product again. In December, Pfizer sold the protein product for $10 million to the Medicines Company. (Pfizer will get more if the new owner revives the drug.)

Indiplon
Pfizer licensed this sleeping pill from Neurocrine Bioscience in 2002 for $200 million—then dumped it in 2006 when the Food and Drug Administration turned it down.

Vicuron Pharmaceuticals
In 2005, Pfizer snared this company for $1.9 billion to gain access to its new antibiotic and new antifungal. The antibiotic has yet to be approved, while the antifungal’s sales were just $18 million last year, according to Bernstein Research.

One Hour Canada

Furnasman New Homes

Furnasman Winnipeg

Dimebon Online

http://www.dimebonalzheimers.com




  • Share/Bookmark
Blog Traffic Exchange Related Websites

Layman's Explanation Dimebon / Dimebolin Treatment Alzheimer's Disease Current Dimebon Studies Underway

Saturday, August 15th, 2009

Researchers have reported promising results for a new Alzheimer’s drug. We take a close look at the evidence, to see whether it might offer a new option for treatment.

What is Known At this Point in Time for the Treatment of Alzheimer’s Disease ?

Alzheimer’s disease is the most common cause of dementia in older people. If someone has dementia, they have trouble with memory and thinking. Their behavior often changes, and eventually they become unable to look after themselves.

There are several treatments to help with the symptoms of dementia, although none of them can cure it. Drugs called cholinesterase inhibitors seem to slow the progress of dementia in some people. However, there’s been a lot of controversy about how well these drugs work.

The National Institute for Health and Clinical Excellence (NICE) is the organisation that decides which treatments can be offered on the NHS. NICE says that three different cholinesterase inhibitors can be used on the NHS, but only for people with moderate Alzheimer’s disease. The drugs aren’t recommended for people in the early stages of Alzheimer’s.

Dementia is likely to be a big problem in future years, as people are living longer on average, so are more likely to get dementia. Doctors are looking for more treatments that may be useful for dementia. One drug being studied at the moment is called dimebon. It’s an antihistamine that was once used to treat allergies. But it was dropped when other allergy drugs were developed. Now, doctors are looking to see if it’s helpful for Alzheimer’s disease.

What does the new study say?

Dimebon worked better than a dummy (placebo) drug for people with mild to moderate Alzheimer’s disease, over six months to a year. People taking dimebon had improved test scores for thinking and memory. People taking the placebo had scores that got worse over the course of the study.

Researchers found the same results using several different tests, all of which looked mainly at how well people could think and remember things.

Tell me more about the study’s findings

The improvement in test scores happened mostly in the first three to six months of the study. Towards the end of 12 months, the average test scores for people taking dimebon had started to go down. But, because the test scores for people who took a placebo went down steadily during the whole 12 months, the people taking dimebon did much better by comparison at the end of the year.

It’s hard to know exactly what the test scores mean. The main test used has a maximum of 70 points. People taking dimebon did about 4 points better than people taking placebo after six months, and 7 points better after a year. That’s a big enough difference for a doctor to notice. But it’s hard to say what that means for the patient. For example, we don’t know whether it would mean someone could stay in their own home, rather than needing care in a nursing home.

People in the study didn’t get many serious side effects from dimebon. A dry mouth was the most common side effect.

Where does the study come from?

The study was carried out in Moscow, Russia, but overseen by researchers at the Baylor College of Medicine in Houston, Texas. It was published in The Lancet, a medical journal owned by a publishing company called Elsevier. It was funded by Medivation, the US company that makes and wants to sell dimebon. It’s quite common for medicine manufacturers to fund medical trials of their drugs.

How reliable are the findings?

The trial was carried out carefully, and over enough time that it should show a real result. It was a type of study called a randomised controlled trial, which is the best sort of study to see if one drug works better than another, or better than a placebo. However, there are some things that should make us cautious.

  • It’s not a very big study. Only 183 patients took part.
  • All the patients were in Russian hospitals. Treatment of Alzheimer’s disease is quite different in Russia, compared to the UK. People tend to be in big wards, in hospitals, and the drugs used in the UK are not widely available. So it’s hard to know whether these results would be the same if the drug was tested in the UK.

The study didn’t compare dimebon with existing drugs for Alzheimer’s disease. It seems to be better than no treatment at all, but we can’t say whether it’s better or worse than the drugs we have already.

What does this mean for me?

If you have Alzheimer’s, or you are caring for someone with the disease, you’ll probably be keen to hear about any potential new treatment. This new study gives some hope that dimebon might be a useful option. But we need to see more research to be sure. Even if more studies show it works well, it’s likely to be several years before dimebon is available as a treatment for Alzheimer’s.

Current Choice Actions for Friends & Family Suffering from Alzheimer’s Disease Dementia

There’s no need to take any action as a result of this study. If you care for someone with Alzheimer’s disease and are worried about their treatment, see your doctor. There are currently three drugs approved in the UK to treat moderate Alzheimer’s. They’re called donepezil, galantamine and rivastigmine.

http://www.guardian.co.uk/lifeandstyle/besttreatments/2008/jul/18/new-alzheimers-treatment-tested

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Dimebon Dimebolin Information Availability

Sunday, March 15th, 2009

Dimebom is a new pharmaceutical treatment alternative for patients suffering from Alzheimer’s Disease.   Dimebon is an older medication that has recently been discovered to be most helpful in treating patients with Alzheimer’s disease.   Dimebom (the actual drug is known chemically as Dimebolin) is an older  Russian antihistamine drug.  It was popularly used in Russia as an antihistamine for hayfever, allergies and the like.  In fact the drug was sold as an easy to obtain antihistamine – sold over the counter without a prescription.

Dimebom is currently in clinical trials in the United States by a company named Medivation .    The website for Medivation, the pharmaceutical company involved with the clinical development and testing of Dimebom in the United States? Can be found at link   www.medivation.com .   To learn more about Medivation’s clinical trials of Dimebom the link is

http://www.medivation.com/pipeline_dimebontrials.html#p3

For more information on CONNECTION study locations, eligibility and enrollment, please visit www.connectionstudy.com or call toll-free 1-877-888-6386

At this point in time Dimebom is not available in any manner to Alzheimer Patients or their families, outside of the study material afforded by the Medivation Company and the Medivation clinical trials themselves.

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com

(more…)

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Early Clinical Pharmacologic Work with Dimebolin as a Adjunct Thereputic Agent

Thursday, January 15th, 2009

Russian research done in the year 2000 has shown beneficial effects of the chemical dimebolin hydrochloride on patients being treated for Alzheimer’s disease.   Indeed using this agent  on what are considered  models of Alzheimer’s disease in animal subjects returned similar results.  Hence the initial models were in place and these were corroborated with early initial testing in human subjects.

The mechanism of the action of the drug seems to be that the agent in its chemical form not only acts as an anti-histamine ( anti histamine)  but also inhibits brain cell death.  Hence dimebolone as a  therepeutic agent shows promise not only in the treatment and treatments of Alzheimer’s Disease  but also in Huntington’s Disease as well as  a host of other neurodegenerative diseases.

The future looks bright for the agent Dimebolin in various thereputic avenues.  More work and progress will need to be done.

Early Clinical Pharmacologic Work with Dimebolin as a Adjunct … – Russian research done in the year 2000 has shown beneficial effects of the chemical dimebolin hydrochloride on patients being treated for Alzheimer?s disease. Indeed using this agent on what are considered models of Alzheimer?s disease …

Dimebon Dimebolin Information Availability – Dimebom is a new pharmaceutical treatment alternative for patients suffering from Alzheimer?s Disease. Dimebon is an older medication that has recently been discovered to be most helpful in treating patients with Alzheimer?s Disease …

antihistamine : Diggs – 2009-Jan-26 : Dimebon Dimebolin … – Dimebon Dimebolin Alzheimer’s Information Availability – Natural Sources of Antihistamine – How Do Antihistamines Work for Allergies?

Call for help. Searching for a drug: Dimebolin – Hello all, My good friend’s father was recently diagnosed with Alzheimer’s disease. He tried several medications with much success. After doing some research he found out that there is a drug called Dimebolin (brand name Dimebon), …

Prous Science – Dimebolin hydrochloride (Dimebon?) is an orally-available, small-molecule agent that is in clinical testing for the treatment of Alzheimer’s and Huntington’s diseases-two progressive, devastating conditions with limited treatment …

Current Research into Dimebon – Dimebon ( chemically or the generic term Dimebolin) has attracted a fair amount of attention both in the medical , lay and popular press. The options available for the treatment of Alzheimer?s patients are limited , the disease is so …

 

 

 

Alzheimer’s Disease Dimebon Over the Counter Russian Anti-histamine

http://dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • 7 Elements of Organic Container Gardening There are seven different, basic elements that are going to be required when you are beginning an organic container garden of any time. These seven elements are water, plants, sunlight,...
  • New Stem Cells Therapy Treating Crohn's Disease Cellular therapy with stem cells is revolutionizing the focus of treatment of many serious diseases. Replacing the cells of damaged tissue with other new cells from the same patient is...
  • 13 Quick Facts About Dementia  If you have a loved one who may have dementia, you need  clear, easy to understand  dementia information which will help you better cope with  their condition.Here are  13  quick  facts about dementia.1.Dementia is a...
  • But wait---there's more: Fosamax has been linked to dead jaw disease as well In the wake of our report on links between atrial fibrillation and bisphosphonate drugs such as Fosamax and Reclast, Health Spectator performed a routine follow-up investigation of the health claims...
  • Stem cell transplants stalled blindness in rats Image via Wikipedia Nerve stem cell transplants may help slow the progression of macular degeneration, the most common cause of blindness in the developed world, U.S. researchers said on Monday....
  • Common Bipolar Disorder Treatments When someone is diagnosed with Bipolar, there are two types of treatments available. These treatments are called: pharmacological and psychotherapeutic. They usually will work so long as the person is...
  • Graft Vs Host Disease Stem Cell Treatment Made Available Lost amidst the Adult stem cell company Osiris’ latest press release announcing their 1rst quarter results for 2009, was a revelation that revealed that their “off the shelf” stem cell...

Current Research into Dimebon

Wednesday, January 14th, 2009

Dimebon ( chemically or the generic term Dimebolin) has attracted a fair amount of attention both in the medical , lay and popular press. The options available for the treatment of Alzheimer’s patients are limited , the disease is so devastating , so that any new therapies or newer therapies that invoke hope are well received.

The problem basically with any new drug , medication or formulations introduced to the marketplace boil down basically to one of numbers and drug interactions. Any medication that is released to the marketplace is basically and essentially only tested on a relatively very small group of patients / victims.

Its not that the testing process is slipshod. It is not and is well is very expensive. Its just that the numbers are relatively small in limited situations. The first thing that is always tested for is safety. If the drug is inherently unsafe then the whole process should be stopped. This potentially does not come into play if the drug will save some people in a situation where nothing else will. Everything in life of course , always comes to risks vs benefits.

The basic problem with drug testing and introduction is simply a matter of numbers , percentages , and interactions with medications or other agents not thought of , or not tested.

It all boils down to statistics and numbers. 1/100 of a percent involving a trial with 100 or even 1000 patients may not uncover damming side effects whereas if that same product is released into the marketplace , with millions of users and patients , and whammo that terrible side effect comes to light now . Not only that when multiplied out , the amount of patients affected adversely is not small , and is indeed large and troubling. The question will be why these interactions and side effects not found , noticed or detected before ?

Which brings up to the beauty of this specific chemical / medication to be used in the treatment of Alzheimer’s Disease.

Dimebon or Dimbolin is an older antihistamine drug which was used in Russia / U.S.S.R. as a widely available medication that was used in great numbers and prevalence for a good period of time. The drug was widely used as it was available easily and widespread without even a prescription. There do not appear to have enough problems with the medication that many problems seem to have be reported with its use.

 

dimebon is cure of alzheimer?s disease? – recently dimebolin has sparked renewed interest after being shown to have positive effects on people suffering from alzheimer?s disease. animal studies showing the potential beneficial effects on alzheimer?s disease models were …

comfort for the afflicted – for example, the antihistamine dimebolin hydrochloride preserved cognition in an 18-month investigation. and the antimalarial methylthioninium chloride interfered with the accumulation of tau tangles in the brain in an 84-week study. …

Pfizer pays $725 Million for experimental drug (Life, Liberty, and … – Pfizer said that it was acquiring the rights to a new experimental substance aimed to help Alzheimer’s disease. The substance (Pictured Above) is Dimebolin, a antihistamine that works on the AMPA/NMDA receptors. …

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Bipolar And Schizophrenia Since Bipolar Disorder and Schizophrenia are very close together in the way they present themselves, it is not hard for even a medical professional to mistake them. Medicines given for...
  • Blood Test to Test for Early Signs of Alzheimers Disease  Has a blood test for diagnosing Alzheimer's disease finally been discovered?Will it be possible to obtain an accurate diagnosis for Alzheimer's instead of the laborious and complicated diagnosis patients receive now?Keep...
  • Canadian Pharmacies Many people are preaching the benefits of choosing a Canadian pharmacy over American pharmacy options, but this opportunity for acquiring your medications across the border may not make sense to...
  • Selling Sickness: Why the drug companies NEED us to be sick. Time for another book report..this time its Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients by Ray Moynihan & Alan Cassels . This book,...
  • Jumpstart Medicine I highly recommend Jumpstart. In fact, I have a special offer for anyone in wanting to try Jumpstart in Redwood City or Mountain View: $25 off your first visit (just...
  • Lindsay Lohan May Have Prescription To Blame For Drug Problems Adderall may have exacerbated any existing issues, expert says.By Gil Kaufman Lindsay Lohan Photo: OutOfSightMedia/ Getty Images It may turn out that the disease that troubled actress Lindsay Lohan isn't...
  • Patients Speak Out About What It Is Really Like To Be Ill Today .!. What's it like to be a patient facing serious illness in today's medical environment? The New York Times has a very detailed series of interviews with real patients facing...

Dimebon Dimebolin Information Availability

Wednesday, January 14th, 2009

Dimebom is a new pharmaceutical treatment alternative for patients suffering from Alzheimer’s Disease

Dimebon is an older medication that has recently been discovered to be most helpful in treating patients with Alzheimer’s Disease

Dimebon ( the actual drug is known chemically as Dimebolin) is an older Russian antihistamine drug.  It was popularly used in Russia as an antihistamine for hayfever , allergies and the like.  In fact the drug was sold as an easy to obtain antihistamine -  sold over the counter without a prescription.

Dimebon is currently in clinical trials in the United States by a company named  Medivation . The website for Medivation company can be found at http://www.medivation.com/

Dimebon and the clinical trial information of Medivation can be found at this link on the internet

http://www.medivation.com/pipeline_dimebontrials.html

At this point in time Dimebon is not available in any manner outside of the study material afforded by the Medivation company and the Medivation clinical trials themselves.

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • RINOs Are the Past Not the Future Sunday Paper - May 10th, 2009 I find it humorous and fascinating that on a daily basis CNN, MSNBC, and the rest of the lame-stream media concern themselves with the...
  • Basics of Alzheimer's Disease Alzheimer's disease is a frightening ailment that affects thousands of people every year. While studies are still being done to determine why exactly this disease hits, research is also being...
  • 5 Tips on Corporate Blogging for Companies Right now, one of the best ways to reach out to your customer base and increase brand recognition is through the use of a corporate blog. However, many companies aren't...
  • How To Fix A Mistake On Your Credit Report. Whether someone alerts you to it or not, sometimes mistakes show up on your credit report. And while I have not had any major things come up, I have had...
  • Corporate Blogging Pitfalls It has been widely recognized that blogging is an excellent way to publish content to a website, and many corporations and other businesses are beginning to embrace this idea with...
  • Stem Cell Therapeutics Corp. Announces Completion of Enrollment Stem Cell Therapeutics Corp. or the  wishes to announce the acceptance and publication of the paper entitled "The Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Study" by the journal "Stroke",...
  • The Story of 900 Cats and Oxygen Therapy The Story of 900 Cats and Oxygen Therapy by: Shafin de Zane, CHT, MH, MNLP A DOCTOR from Maryland, USA sued KFC for using a cooking oil that contains high...